Prime Medicine, Inc.
PRME
$1.24
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 4.99% | 20.03% | 36.53% | 48.95% | 70.54% |
| Gross Profit | -2.98% | -19.44% | -36.03% | -48.38% | -70.54% |
| SG&A Expenses | 15.61% | 27.59% | 31.33% | 38.60% | 45.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.40% | 21.75% | 35.32% | 46.47% | 64.14% |
| Operating Income | -5.84% | -21.29% | -34.94% | -46.04% | -64.14% |
| Income Before Tax | 1.28% | -27.29% | -44.49% | -48.15% | -61.61% |
| Income Tax Expenses | 100.00% | 100.00% | 25.52% | 109.22% | 70.57% |
| Earnings from Continuing Operations | 1.14% | -27.64% | -44.56% | -48.86% | -62.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.14% | -27.64% | -44.56% | -48.86% | -62.64% |
| EBIT | -5.84% | -21.29% | -34.94% | -46.04% | -64.14% |
| EBITDA | -5.20% | -21.02% | -34.69% | -45.62% | -63.26% |
| EPS Basic | 23.44% | -2.01% | 29.38% | 50.24% | 60.45% |
| Normalized Basic EPS | 18.16% | 2.14% | 27.35% | 42.48% | 51.42% |
| EPS Diluted | 23.44% | -2.01% | 29.38% | 50.24% | 60.45% |
| Normalized Diluted EPS | 18.16% | 2.14% | 27.35% | 42.48% | 51.42% |
| Average Basic Shares Outstanding | 30.37% | 26.13% | 47.84% | 84.36% | 168.13% |
| Average Diluted Shares Outstanding | 30.37% | 26.13% | 47.84% | 84.36% | 168.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |